At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 169 enrolled
Drug / intervention
Setipiprant +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males
In Brief
A Phase 2 clinical trial evaluating Setipiprant, Placebo, and 1 other intervention for Alopecia. Completed, enrolled 169 participants across 18 sites.
Detailed Summary
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartJul 2016
Primary CompletionMar 2018
Study CompletionMay 2018
TodayJul 2026
First PostedMay 24, 2016
Enrollment StartJul 14, 2016
Primary CompletionMar 15, 2018
Study CompletionMay 22, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.1 years ago
Interventions
Setipiprantdrug
Setipiprant tablets, orally, BID for 24 weeks.
Placebodrug
Placebo tablets, orally, BID for 24 weeks.
Finasteridedrug
Finasteride tablet, orally, once daily for 24 weeks.